title: A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Emil
authors.initials: E
authors.lastname: Lou
authors.forename: John
authors.initials: J
authors.lastname: Marshall
authors.forename: Mebea
authors.initials: M
authors.lastname: Aklilu
authors.forename: David
authors.initials: D
authors.lastname: Cole
authors.forename: David
authors.initials: D
authors.lastname: Chang
authors.forename: Michael
authors.initials: M
authors.lastname: Morse
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D019496:Cancer Vaccines / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003713:Dendritic Cells; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
chemical_list: D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C479602:rF-TRICOM vaccine